| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Legal > Personal Injury > A Philadelphia Personal Injury Lawyer Talks About Traumatic Brain Injury and Brain Injury Claims |
|
Top Articles - A Philadelphia Personal Injury Lawyer Talks About Traumatic Brain Injury and Brain Injury Claims
According to the National Institutes of Health, “Traumatic brain injury (TBI), broadly defined as brain injury According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product from externally inflicted trauma, may result in significant impairment of an individual's physical, cognitive, ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in and psychosocial functioning. In the United States, an estimated 1.5 to 2 million people incur TBI each year, p lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. incipally as a result of vehicular incidents, falls, acts of violence, and sports accidents. The number of peop here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe le surviving TBI with impairment has increased significantly in recent years, which is attributed to faster and d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro more effective emergency care, quicker and safer transportation to specialized treatment facilities, and advanc ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc es in acute medical management. TBI affects people of all ages and is the leading cause of long-term disability easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi among children and young adults. Each year, approximately 70,000 to 90,000 individuals incur a TBI resulting i nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically n a long-term, substantial loss of functioning. The consequences of TBI include a dramatic change in the indivi and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ual's life-course, profound disruption of the family, enormous loss of income or earning potential, and large e ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi xpenses over a lifetime. There are approximately 300,000 hospital admissions annually for persons with mild or ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a moderate TBI, and an additional unknown number of traumatic brain injuries (TBIs) that are not diagnosed but ma dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod result in long-term disability.” TBI results principally from vehicular accidents, falls, acts of violence, a cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin nd sports injuries. It is more than twice as likely in males than in females. The highest incidence is among tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ersons 15 to 24 years of age and 75 years and older. Given the large toll of TBI and absence of a cure, preven t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel tion is of paramount importance. Available evidence supports the use of certain cognitive and behavioral rehab ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust litation strategies for individuals with TBI. Increased understanding of the mechanisms of TBI and recovery ho y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ld promise for new treatments. Persons with TBI, their families, and significant others are integral to the im . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de lementation of the rehabilitation process and research. Rehabilitation services, matched to the needs of person elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip s with TBI, and community-based nonmedical services are needed to optimize outcomes over the course of recovery tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Email Marketing - How to Email Market in 2006 Confessions of a Google AdWords Winner - Part 1 Bridge To Cross The Hurdle Of Money – Bridging Loans
|